Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)

MLA

Sabine Furst, et al. “Outcome and Long-Term Follow-up of Alloreactive Donor Lymphocyte Infusions given for Relapse after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantations (HSCT).” Bone Marrow Transplantation, vol. 35, Jan. 2005, pp. 601–08. EBSCOhost, https://doi.org/10.1038/sj.bmt.1704807.

APA

Sabine Furst, Anne-Sophie Michallet, L. Gebuhrer, S. Hayette, J P Tremisi, Valérie Dubois, Q H Le, J P Bourgeot, Xavier Thomas, Marie-Cécile Michallet, & Franck-Emmanuel Nicolini. (2005). Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplantation, 35, 601–608. https://doi.org/10.1038/sj.bmt.1704807

Chicago

Sabine Furst, Anne-Sophie Michallet, L. Gebuhrer, S. Hayette, J P Tremisi, Valérie Dubois, Q H Le, et al. 2005. “Outcome and Long-Term Follow-up of Alloreactive Donor Lymphocyte Infusions given for Relapse after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantations (HSCT).” Bone Marrow Transplantation 35 (January): 601–8. doi:10.1038/sj.bmt.1704807.